Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma

Next Previous
Trial Profile

A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Vimseltinib (Primary)
  • Indications Fibroma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Apr 2025 Planned End Date changed from 22 Jan 2025 to 22 Jan 2026.
  • 24 Apr 2025 Planned primary completion date changed from 22 Jan 2025 to 22 Jan 2026.
  • 24 Apr 2024 Planned End Date changed from 22 Jan 2024 to 22 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top